National
‘Very familiar’: Mark Glaze’s story brings into focus mental health for gay men
Experts see common story as LGBTQ people enter middle age
The death by suicide at age 51 of Mark Glaze, a gun reform advocate who was close to many in D.C.’s LGBTQ community, is striking a chord with observers who see his struggles with mental health and alcoholism as reflective of issues facing many gay men as they enter middle age.
Glaze’s story resonates even though much of the attention on mental health issues in the LGBTQ community is devoted to LGBTQ youth going through the coming out process and transgender people who face disproportionate violence and discrimination within the LGBTQ community in addition to a growing focus on LGBTQ seniors entering later stages of life.
Randy Pumphrey, senior director of behavioral health for the D.C.-based Whitman-Walker Health, said Glaze’s story was “very familiar” as a tale of mental health issues facing gay men in the middle stage of life.
“You’re talking about a gay-identified man who is in his 50s, somebody who has struggled with alcohol misuse — or maybe abuse or dependence— and also depression,” Pumphrey said. “I think that there has always been a higher incidence of suicide for men in general in their middle age 50 and above, but this increases when you’re talking about gay men, and also if you’re talking about gay men who suffer with mental health issues, or substance use disorder issues.”
Several sources close to Glaze said his death did not come as a surprise. His family has been open about his death by suicide last month while he was in jail after allegedly fleeing the scene of a car accident in Pennsylvania and a long history of depression and alcoholism.
Pumphrey said Glaze’s situation coping with mental health issues as well as the consequences for his role in the accident, were reflective of someone who might “begin to perceive that this is an issue that they can’t get away from, or the consequences they can’t get away from exposure and that can lead somebody to a fatal outcome.”
“My experience is that there have been gay men that I have worked with over the years — particularly in their 50s and early 60s — it’s taken them a long time to recognize the severity of the problem, whether it’s their depression or their substance abuse, and then they find themselves in a very precarious situation because of shame, and so they may not necessarily seek help even though they need help.”
A 2017 study in the American Journal of Men’s Health found the prevalence of depression among gay men is three times higher than the general adult population, which means they are a subgroup at high risk for suicide.
The study found “scant research exists about gay men’s health beyond sexual health issues,” most often with HIV, which means issues related to depression and suicidality “are poorly understood.”
“Gay men’s health has often been defined by sexual practices, and poorly understood are the intersections of gay men’s physical and mental health with social determinants of health including ethnicity, locale, education level and socioeconomic status,” the study says.
The study acknowledged being male itself is one factor incorporated in addressing mental health issues in this subgroup because “regardless of sexual orientation, men can be reluctant to seek help for mental health problems.” Another study quoted in the report found 23 percent, less than one quarter of gay men, who attempted suicide sought mental health or medical treatment.
In addition to mental health issues facing gay men in Glaze’s age group, others saw his situation as a common story in the culture of Washington, which is notorious for celebrating and prioritizing success with little tolerance for personal setbacks.
In the case of Glaze, who had sparred on Fox News with Tucker Carlson as executive director of Everytown for Gun Safety, the threat of exposure and threat to his career may have seemed overwhelmingly daunting.
Steven Fisher, who knew Glaze since the 1990s and worked with him at the D.C.-based Raben Group, said one factor that contributed to Glaze’s condition was “he could only see upward in terms of his career trajectory.”
“We saw that in him and it had me very concerned because I felt like he might end up in a place that wasn’t good once he left Everytown, and that’s tragically and sadly what happened,” Fisher said. “I think he just had trouble adjusting to what is usually a roller coaster ride, I think, in people’s careers, especially in the D.C. world.”
Along with Glaze, Fisher has worked on gun issues for Everytown, which has been a client of his since 2015 after he worked for them in 2012 after the Newtown shooting.
Compounding the challenges that Glaze faced is a culture among many gay men focused on sexuality, which prioritizes youth and appearance and presents problems as those qualities start fading when men enter middle age.
Fisher said another factor in Glaze’s condition was social media, pointing out public perception about his identity was important to him.
“If you look at his social media — I think this is instructive to the rest of us — a lot of the comments are about how Mark was so good looking and he was charming, and he was so smart and so funny,” Fisher said. “That’s all true, and that’s why he was very appealing to many people, but those qualities don’t really tell you everything about a person. In fact, one could argue they’re superficial in a way, and people have to remember people are more complicated than what you see on social media.”
One issue for gay men facing mental health issues as they enter middle age is they don’t have the same resources as those available to LGBTQ youth, who have been more of a focus in terms of mental health issues in the LGBTQ community.
Among the leading organizations for LGBTQ youth is the Trevor Project, which has resources and a hotline for LGBTQ youth facing mental health crises.
Kevin Wong, vice president of communications for the Trevor Project, said his organization would be receptive to an older LGBTQ person who calls the hotline, but ultimately would refer that person elsewhere.
“If an LGBTQ person above the age of 25 reaches out to The Trevor Project’s crisis services for support and expresses suicidal thoughts, our counselors will listen, actively and with empathy, and work with them to de-escalate and form a safety plan, like any other contact,” Wong said. “However, our organization has remained youth-centric since its founding and our volunteer crisis counselors are specifically trained with younger LGBTQ people in mind.”
Much attention is focused on the coming out process for LGBTQ people, a time that can upend close relationships — as well as reaffirm them — and a process more commonly associated with youth.
Ilan Meyer, senior scholar of public policy at the Williams Institute at the University of California, Los Angeles, said data is scant about suicide rates among LGBTQ people, but information on suicide attempts shows they tend to be at a heightened rate for LGBTQ people as they go through the coming out process.
“What we do know is that there is a connection with the coming out period at whatever age coming out happens,” Meyer said. “And so, we see a proximity to coming out whatever age that happened, we see the suicide attempts proceeding and after that.”
Suicide attempts, Meyer said, are much higher for LGBTQ people than the population at large. The self-reported rate of suicide attempts in the U.S. population as a whole, Meyer said, is 2.4 percent, but that figure changes to 20 to 30 percent among LGBTQ youth, which about to 10 to 15 times greater.
Black and Latino people, Meyer said, have been less likely to make suicide attempts in their lifetimes, although he added that may be changing in recent years.
With the primary focus on mental health issues elsewhere in the LGBTQ community, Glaze’s death raises questions about whether sufficient resources are available to people in his demographic, or whether individuals are willing to seek out care options that are available.
Meyer said whether the resources for suicidal ideologies among LGBTQ people are sufficient and what more could be done “is the the million-dollar question.”
“It’s definitely not determined by just mental health,” Meyer said. “So many people have depression, but they don’t attempt suicide. And so, then the difficult thing is to find the right moment to intervene and what that intervention should be.”
Meyer said much of the focus on mental health is on a person’s last moments before making a suicide attempt, such as making suicide hotlines readily available, but some of the stressors he sees “are more chronic, ongoing things related to homophobia and the kind of experience that LGBT people have as they come to terms to realize their sexual identity.”
Pumphrey said another factor in mental health issues not to be underestimated for almost two years now is “dealing with the COVID and loneliness epidemic,” which appears to have no immediate end in sight with the emergence of the Omnicron variant.
“There was always this piece of sometimes the experience of being in your 50s and early 60s…we talk about the invisibility factor,” Pumphrey said. “But when there’s just this sense of being disconnected from community, especially in the early days of the pandemic, and kind of being locked down, I think that just raised the risk.”
Federal Government
Holiday week brings setbacks for Trump-Vance trans agenda
Federal courts begin to deliver end-of-year responses to lawsuits involving federal transgender healthcare policy.
While many Americans took the week of Christmas to rest and relax, LGBTQ politics in the U.S. continued to shift. This week’s short recap of federal updates highlights two major blows to the Trump-Vance administration’s efforts to restrict gender-affirming care for minors.
19 states sue RFK Jr. to end gender-affirming care ban
New York Attorney General Letitia James announced on Tuesday that the NYAG’s office, along with 18 other states (and the District of Columbia), filed a lawsuit to stop U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. from restricting gender-affirming care for minors.
In the press release, Attorney General James stressed that the push by the Trump-Vance administration’s crusade against the transgender community — specifically transgender youth — is a “clear overreach by the federal government” and relies on conservative and medically unvalidated practices to “punish providers who adhere to well-established, evidence-based care” that support gender-affirming care.
“At the core of this so-called declaration are real people: young people who need care, parents trying to support their children, and doctors who are simply following the best medical evidence available,” said Attorney General James. “Secretary Kennedy cannot unilaterally change medical standards by posting a document online, and no one should lose access to medically necessary health care because their federal government tried to interfere in decisions that belong in doctors’ offices. My office will always stand up for New Yorkers’ health, dignity, and right to make medical decisions free from intimidation.”
The lawsuit is a direct response to HHS’ Dec. 18 announcement that it will pursue regulatory changes that would make gender-affirming health care for transgender children more difficult, if not impossible, to access. It would also restrict federal funding for any hospital that does not comply with the directive. KFF, an independent source for health policy research, polling, and journalism, found that in 2023 federal funding covered nearly 45% of total spending on hospital care in the U.S.
The HHS directive stems directly from President Donald Trump’s Jan. 28 Executive Order, Protecting Children From Chemical and Surgical Mutilation, which formally establishes U.S. opposition to gender-affirming care and pledges to end federal funding for such treatments.
The American Medical Association, the nation’s largest and most influential physician organization, has repeatedly opposed measures like the one pushed by President Trump’s administration that restrict access to trans health care.
“The AMA supports public and private health insurance coverage for treatment of gender dysphoria and opposes the denial of health insurance based on sexual orientation or gender identity,” a statement on the AMA’s website reads. “Improving access to gender-affirming care is an important means of improving health outcomes for the transgender population.”
The lawsuit also names Oregon, Washington, California, Colorado, Connecticut, Delaware, the District of Columbia, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Mexico, Pennsylvania, Rhode Island, Vermont, and Wisconsin as having joined New York in the push against restricting gender-affirming care.
At the HHS news conference last Thursday, Jim O’Neill, deputy secretary of the department, asserted, “Men are men. Men can never become women. Women are women. Women can never become men.”
DOJ stopped from gaining health care records of trans youth
U.S. District Judge Cathy Bissoon blocked an attempt by the Department of Justice (DOJ) to gain “personally identifiable information about those minor transgender patients” from the University of Pittsburgh Medical Center (UPMC), saying the DOJ’s efforts “fly in the face of the Supreme Court.”
Journalist Chris Geidner originally reported the news on Dec. 25, highlighting that the Western District of Pennsylvania judge’s decision is a major blow to the Trump-Vance administration’s agenda to curtail transgender rights.
“[T]his Court joins the others in finding that the government’s demand for deeply private and personal patient information carries more than a whiff of ill intent,” Bissoon wrote in her ruling. “This is apparent from its rhetoric.”
Bissoon cited the DOJ’s “incendiary characterization” of trans youth care on the DOJ website as proof, which calls the practice politically motivated rather than medically sound and seeks to “…mutilate children in the service of a warped ideology.” This is despite the fact that a majority of gender-affirming care has nothing to do with surgery.
In United States v. Skrmetti, the Supreme Court ruled along party lines that states — namely Tennessee — have the right to pass legislation that can prohibit certain medical treatments for transgender minors, saying the law is not subject to heightened scrutiny under the Equal Protection Clause of the Fourteenth Amendment because it does not involve suspect categories like race, national origin, alienage, and religion, which would require the government to show the law serves a compelling interest and is narrowly tailored, sending decision-making power back to the states.
“The government cannot pick and choose the aspects of Skrmetti to honor, and which to ignore,” Judge Bissoon added.
The government argued unsuccessfully that the parents of the children whose records would have been made available to the DOJ “lacked standing” because the subpoena was directed at UPMC and that they did not respond in a timely manner. Bissoon rejected the timeliness argument in particular as “disingenuous.”
Bissoon, who was nominated to the bench by then-President Obama, is at least the fourth judge to reject the DOJ’s attempted intrusion into the health care of trans youth according to Geidner.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
Out actor talks lead role in ‘Fiddler on the Roof’
This gay author sees dead people
Holiday week brings setbacks for Trump-Vance trans agenda
Your guide to D.C.’s queer New Year’s Eve parties
Long-awaited ‘Pillion’ surpasses the sexy buzz
Reasons to be optimistic about 2026
Long-awaited ‘Pillion’ surpasses the sexy buzz
Trump’s ‘American people derangement syndrome’
Using movement to boost your mental health during holidays
